SAN DIEGO, May 2, 2017 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company
focused on developing novel, small molecule drugs across multiple
therapeutic areas, today announced that the Company will release
its first quarter 2017 financial results and provide a corporate
update on Tuesday, May 9, 2017, after
the close of the U.S. financial markets. The Company will
host a conference call and live webcast with the investment
community the same day at 4:30 p.m.
ET.
Conference Call & Webcast Information
When:
May 9, 2017, 4:30 p.m. ET
Dial-in: (877) 643-7155 (United
States) or (914) 495-8552 (International)
Conference ID: 8556129
Please join the conference call at least 10 minutes early to
register. You can access the live webcast under the investor
relations section of Arena's website at:
www.arenapharm.com. A replay of the conference call will be
archived under the investor relations section of Arena's website
for 30 days after the call.
About Arena Pharmaceuticals
Arena Pharmaceuticals is a
biopharmaceutical company focused on developing novel, small
molecule drugs with optimized receptor pharmacology designed to
deliver broad clinical utility across multiple therapeutic areas.
Our proprietary pipeline includes potentially first- or
best-in-class programs for which we own global commercial
rights. Our three most advanced investigational clinical
programs are ralinepag (APD811) in Phase 2 evaluation for pulmonary
arterial hypertension (PAH), etrasimod (APD334) in Phase 2
evaluation for multiple autoimmune indications, and APD371 in Phase
2 evaluation for the treatment of pain associated with Crohn's
disease. In addition, Arena has collaborations with the following
pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc.
(commercial stage), Axovant Sciences (Phase 2 candidate), and
Boehringer Ingelheim International GmbH (preclinical
candidate).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about Arena's focus, and the potential of its programs
and collaborations. For such statements, Arena claims the
protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Arena's
expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include those
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Contact:
Kevin R. Lind,
Chief Financial Officer
klind@arenapharm.com
858.210.3636
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-release-first-quarter-2017-financial-results-and-provide-corporate-update-on-tuesday-may-9-2017-300449034.html
SOURCE Arena Pharmaceuticals, Inc.